

### Certificate of analysis

DRICUi029-A

Operator: SH Ellwood Date: 30/06/2023

Supervisor: SA Cowley Date: 02/08/2023

Signature: SA Cousley


### Source of cells and reprogramming information

- MW14A10014A T cells from Cardiff 26/07/2022
- Reprogrammed at UOXF AKA IPMAR34 Reprogrammed on 08/2022 SC/SE
- Reprogramming system Cytotune v2
- Clone DRICUi029-A = IPMAR34A1
- Banked at p13 11/2022 SE


## Viability post-thaw and Morphology according to JMSCFSOP19 passage 14

- Vial cell count immediately post-thaw 1.46 x 10<sup>6</sup>
- Viability immediately post-thaw 83.7%
- Photo at day 3 post-thaw (scale bar = 100μm):

Day 3 post-thaw, 20% plated to 1w.6wp



## Sendai Cytotune 2 clearance: according to Cytotune manual Virus undetectable at passage 10



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp

#### Sterility:

Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 14.

Visual inspection of thawed cells cultured without antibiotic/antimycotic for 4 days: no evidence of bacteria, yeast or fungus.

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				6.804	128.2	18.84
-ve control				8.928	0.872	0.10
	IPMAR34A1 DRICUi029-A	p14	SE	1.792	0.681	0.38

Results mean:


Ratio 0 - 0.999 negative for mycoplasma

Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

# Flow cytometric analysis according to JMSCFSOP05 passage 14

DRICUi029 Tra-1-60 84.2%




DRICUi029 Nanog 73.1%




## Illumina GSA SNP analysis according to JMSCFSOP16

- Passage 13
- Identity to parent PBMC confirmed
- Karyotype abnormalities:
  - No gross abnormalities detected vs PBMC

## Alignment of MW14A10014A PBMC SNPs with DRICUi029-A



### Karyogram MW14A10014A PBMC



### Karyogram DRICUi029-A

